Abstract
The drug delivery system described here is based on a virus like particle consisting of the recombinant expressed major capsid protein of Polyomavirus, VP1. Polyoma, a murine virus belonging to the Papovaviridae, forms a non-enveloped icosahedral capsid. These capsids are organized as a double shell composed of three different proteins: VP1,VP2 and VP3. The outer shell of the vision is composed of 360 VP1 molecules arranged as 72 pentamers. These capsids have a diameter of about 50 nm. The VP1 protein acts as a major ligand for certain membrane receptors during virus infection. Furthermore, the N-terminus of the VP1 protein contains a DNA-binding domain and a nuclear localization sequence. The recombinant production of the VP1 protein offers a save way to obtain a highly purified, non-pathogenic pharmaceutical excipient. Combining these aspects, VP1 proteins provide a targeting as well as a drug binding site when used as a save drug carrier for gene therapy. Current applications are also including oligonucleotides as well as small molecules as well as vaccines.
Keywords: artificial virus, virus like particle, vp1 capsids, drug delivery system
Current Pharmaceutical Biotechnology
Title: Recombinant Virus Like Particles as Drug Delivery System
Volume: 6 Issue: 1
Author(s): Christiane Georgens, Jorg Weyermann and Andreas Zimmer
Affiliation:
Keywords: artificial virus, virus like particle, vp1 capsids, drug delivery system
Abstract: The drug delivery system described here is based on a virus like particle consisting of the recombinant expressed major capsid protein of Polyomavirus, VP1. Polyoma, a murine virus belonging to the Papovaviridae, forms a non-enveloped icosahedral capsid. These capsids are organized as a double shell composed of three different proteins: VP1,VP2 and VP3. The outer shell of the vision is composed of 360 VP1 molecules arranged as 72 pentamers. These capsids have a diameter of about 50 nm. The VP1 protein acts as a major ligand for certain membrane receptors during virus infection. Furthermore, the N-terminus of the VP1 protein contains a DNA-binding domain and a nuclear localization sequence. The recombinant production of the VP1 protein offers a save way to obtain a highly purified, non-pathogenic pharmaceutical excipient. Combining these aspects, VP1 proteins provide a targeting as well as a drug binding site when used as a save drug carrier for gene therapy. Current applications are also including oligonucleotides as well as small molecules as well as vaccines.
Export Options
About this article
Cite this article as:
Georgens Christiane, Weyermann Jorg and Zimmer Andreas, Recombinant Virus Like Particles as Drug Delivery System, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167202
DOI https://dx.doi.org/10.2174/1389201053167202 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies
Current Drug Safety Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Severe Preeclampsia
Current Women`s Health Reviews Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization
Current Medical Imaging Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Plasma Infusions into Porcine Cerebral White Matter Induce Early Edema, Oxidative Stress, Pro-Inflammatory Cytokine Gene Expression and DNA Fragmentation: Implications for White Matter Injury with Increased Blood- Brain-Barrier Permeability
Current Neurovascular Research Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatininduced Cardiotoxicity and Neurotoxicity in Rodents
Current Medicinal Chemistry Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry